Streetbeat News

ESALY

Eisai Co Ltd

https://www.eisai.co.jp/

CEO

Haruo Naito

Industry

Pharmaceutical Preparation Manufacturing

Open

62.35

Mkt cap

18B

Volume

332K

High

63.29

P/E Ratio

20.54

52-wk high

73.90

Low

61.00

Div yield

N/A

52-wk low

36.88

LuMind CEO Hampus Hillerstrom is advocating for access to Alzheimer's drugs made by Eisai Co Ltd (OTC:ESALY)/ Biogen Inc's (NASDAQ:BIIB) and Eli Lilly And Co's (NYSE:LLY) for people with Down syndrome. Hillerstrom is at odds with neurologists who recommend against immediate use, citing untested safety risks. Advocacy groups are lobbying Eisai and Lilly to conduct safety trials specifically for Down syndrome and for Medicare policy changes to ensure these individuals are not disqualified from treatment reimbursements.

Portfolio Pulse from Vandana Singh

October 10, 2023 | 4:35 pm

Japan's regulatory authority has approved Leqembi, an Alzheimer's treatment developed by Eisai Co Ltd and Biogen Inc. The approval is based on Phase 3 data from the global Clarity AD clinical trial, which showed statistically significant results and confirmed the clinical benefit of Leqembi. Eisai will conduct a post-marketing survey in all patients administered Leqembi.

Portfolio Pulse from Vandana Singh

September 25, 2023 | 2:41 pm

Merck & Co Inc and Eisai Co Ltd have announced that two Phase 3 trials, LEAP-006 and LEAP-008, evaluating Keytuda plus Lenvima in patients with certain types of metastatic non-small cell lung cancer, did not meet their primary endpoints. The safety profiles of the treatment regimens were consistent with previous studies. Keytruda plus Lenvima is approved in the U.S., the EU, Japan, and other countries for advanced renal cell carcinoma and certain types of advanced endometrial carcinoma.

Portfolio Pulse from Vandana Singh

September 22, 2023 | 2:21 pm

Merck & Co Inc and Eisai Ltd have announced the discontinuation of the Phase 3 LEAP-010 trial evaluating Keytruda plus Lenvima for recurrent or metastatic head and neck squamous cell carcinoma. The decision was made after the therapy failed to show an improvement in overall survival in the second analysis. This follows the discontinuation of the LEAP-017 and LEAP-003 trials earlier this year and the LEAP-002 trial last year.

Portfolio Pulse from Vandana Singh

August 25, 2023 | 3:58 pm

The FDA has approved a supplemental marketing application for Biogen Inc (NASDAQ:BIIB) and Eisai Co Ltd's (OTC:ESALY) Leqembi, the first approved treatment shown to reduce the rate of disease progression in adults with Alzheimer's disease. Concurrently, CMS confirmed broader Medicare coverage for Leqembi. Analysts from William Blair, Raymond James, Oppenheimer, and Needham provided their perspectives on the development, with a general consensus that the approval and expanded coverage may not significantly change the outlook for Leqembi.

Portfolio Pulse from Vandana Singh

July 07, 2023 | 5:25 pm

Senator Bernie Sanders has vowed to oppose all health agency nominees, including Monica Bertagnolli for NIH director, until the Biden administration presents a plan to lower prescription drug prices. Sanders has urged the HHS to address the high cost of Eisai Co Ltd and Biogen Inc's Alzheimer's treatment Leqembi.

Portfolio Pulse from Vandana Singh

June 14, 2023 | 5:52 pm

Alzheimer's drug Leqembi, developed by Eisai Co Ltd and Biogen Inc, faces hurdles in Europe due to concerns over health risks and healthcare resources. The drug is undergoing regulatory review in Europe and is likely to receive approval in the U.S. next month. However, European countries prioritize cost-effectiveness, and analysts predict a smaller European market for the drug.

Portfolio Pulse from Vandana Singh

June 13, 2023 | 12:30 pm

The FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted unanimously in favor of Eisai and Biogen's Leqembi for Alzheimer's disease, confirming its clinical benefit. The committee also confirmed the overall benefit-risk profile of Leqembi and the clinical meaningfulness of the data.

Portfolio Pulse from Vandana Singh

June 12, 2023 | 6:01 pm

Senator Bernie Sanders has urged the U.S. Department of Health and Human Services (HHS) to address the high cost of Eisai Co Ltd and Biogen Inc's Alzheimer's treatment Leqembi, calling its $26,500 annual price tag 'unconscionable'. Sanders suggested breaking the patent monopoly or restricting the amount paid by Medicare and Medicaid Services for the drug.

Portfolio Pulse from Vandana Singh

June 08, 2023 | 3:27 pm

Amazon considers launching an ad-supported Prime Video tier to boost its ad business and entertainment revenue. Google and Microsoft face backlash for including ads in AI trials without opt-out options. Airbus records a 34% YoY increase in May deliveries.

Portfolio Pulse from Vandana Singh

June 08, 2023 | 12:39 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.